Tier 2 — strong

Long-term treatment with oral N-acetylcysteine: affects lung function but not sputum inflammation in cystic fibrosis subjects. A phase II randomized placebo-controlled trial

C Conrad, J Lymp, V Thompson, C Dunn, Z Davies, B Chatfield, D Nichols, J Clancy, R Vender, M E Egan, L Quittell, P Michelson, V Antony, J Spahr, R C Rubenstein, R B Moss, L A Herzenberg, C H Goss, R Tirouvanziam
J Cyst Fibros 2015 14(2):219-227

Bibliography

PubMed
PMID 25228446
DOI
10.1016/j.jcf.2014.08.008
Funding
Funding disclosure was not located in the indexed record reviewed; consult the source publication for the full funding statement.
Competing interests
Competing-interest disclosure was not located in the indexed record reviewed; consult the source publication for the full declaration.

Study snapshot

DesignPhase II randomized placebo-controlled trial
ModelHuman
SamplePeople with cystic fibrosis
InterventionOral NAC versus placebo
DurationClinical trial treatment period
EndpointsGlutathione/redox markers; Pulmonary outcomes; Safety

What the study showed, in plain terms

Phase II trial examining NAC in cystic fibrosis, where mucus, inflammation and glutathione biology are all relevant.

Key findings

Provides disease-specific randomized evidence but does not establish NAC as a general respiratory supplement.

What this study can and cannot tell us

Cystic-fibrosis population and trial-specific endpoints; not directly transferable to COPD or healthy adults.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology